Engineered CXCL12 alpha locked dimer polypeptide

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9346871
APP PUB NO 20130316944A1
SERIAL NO

13936650

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides a novel CXCL12-α2 locked dimer polypeptide, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
THE MEDICAL COLLEGE OF WISCONSINMILWAUKEE WI

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Peterson, Francis C Racine, US 92 3682
Sakmar, Thomas New York, US 4 10
Seibert, Christoph H Frankfurt am Main, DE 4 10
Veldkamp, Christopher T Milwaukee, US 4 10
Volkman, Brian F Muskego, US 9 10

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Nov 24, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00